Search results
Search for "antibodies" in Full Text gives 69 result(s) in Beilstein Journal of Organic Chemistry.
Isocyanide-based multicomponent reactions towards cyclic constrained peptidomimetics
Beilstein J. Org. Chem. 2014, 10, 544–598, doi:10.3762/bjoc.10.50
- , they are interesting starting points for the development of novel drugs [1][2]. Peptides may act as neurotransmitters, hormones or antibodies and are involved in the progress of several diseases. However, natural peptides and proteins possess several properties which make them less suitable as a drug
SF002-96-1, a new drimane sesquiterpene lactone from an Aspergillus species, inhibits survivin expression
Beilstein J. Org. Chem. 2013, 9, 2866–2876, doi:10.3762/bjoc.9.323
- Diagnostics, Mannheim, Germany)). 25 µg total cell extracts were subjected to 10% SDS-PAGE, transferred onto a nitrocellulose membrane, probed with antibodies specific for human survivin (1:1000, 71G4B7, New England Biolabs Frankfurt/M) or β-actin (1:1000, 13E5, New England Biolabs Frankfurt/M) and then with
- IL-6 (for Stat3) and 10 ng/mL TNF-α, 5 ng/mL IL-1β (for NF-κB) for 30 min. Chromatin was cross-linked and immunoprecipitated using antibodies against Stat3, NF-κB p65, acetylated histone 3 (H3K9Ac) or rabbit IgG. DNA isolated from immunoprecipitates or from total chromatin preparation before
The regulation and biosynthesis of antimycins
Beilstein J. Org. Chem. 2013, 9, 2556–2563, doi:10.3762/bjoc.9.290
- monoclonal anti-His antibodies were unsuccessful because His6-σAntA does not complement the antA mutant strain of S. albus S4, suggesting the protein is inactive. Furthermore, polyclonal antibodies raised against purified σAntA reacted with the purified σAntA protein in immunoblotting experiments, but could
Synthesis and evaluation of cell-permeable biotinylated PU-H71 derivatives as tumor Hsp90 probes
Beilstein J. Org. Chem. 2013, 9, 544–556, doi:10.3762/bjoc.9.60
- cell homogenates, these compounds may be further used to investigate Hsp90 complexes in live cells, which represents a more physiologically relevant state. These tools also have use in flow cytometry and microscopy, whereby fluorescently labeled antibodies to biotin are used, as we describe below
Chemical modification allows phallotoxins and amatoxins to be used as tools in cell biology
Beilstein J. Org. Chem. 2012, 8, 2072–2084, doi:10.3762/bjoc.8.233
- oleic acid or polylysine and thus decrease the medium concentration necessary to achieve growth inhibition down to the nanomolar range. Amanitin as a drug bound to tumor monoclonal antibodies, has recently been described for the therapy of adenocarcinomas [34]. Coupling to methoxypolyethyleneglycol has
Peptides presenting the binding site of human CD4 for the HIV-1 envelope glycoprotein gp120
Beilstein J. Org. Chem. 2012, 8, 1858–1866, doi:10.3762/bjoc.8.214
- range of broadly neutralizing anti-HIV-1 antibodies, such as mAb b12 [7] and mAb VRC01 [8], overlap the CD4 binding site (CD4bs) of gp120, making this region of gp120 an important target for immunogen design. Therefore, we have previously designed and generated a synthetic peptide that presents the
- involving recombinant proteins, i.e., gp120, and soluble CD4 (sCD4) presenting the extracellular CD4 domains, in conjunction with the use of antibodies that recognize the coreceptor binding site of gp120 (CD4i antibodies) as coreceptor surrogates [8]. Similar to sCD4, the cyclic peptide CD4-M5, which
Synthesis of 4” manipulated Lewis X trisaccharide analogues
Beilstein J. Org. Chem. 2012, 8, 1134–1143, doi:10.3762/bjoc.8.126
- -GlcNAcp), at the nonreducing end, and this antigenic determinant is also present at the surface of many normal cells and tissues, which include kidney tubules, gastrointestinal epithelial cells, and cells of the spleen and brain [7][8][9][10][11]. Indeed, anti-Lex monoclonal antibodies (e.g., FH3, SH1
- consider is an expected autoimmune response to the native Lex antigen. Fortunately an internal epitope displayed by dimLex was discovered when monoclonal antibodies (mAbs) FH4 and SH2, raised against dimLex, were isolated. Indeed, these mAbs were shown to bind to the dimLex and trimLex antigens but only
- weakly recognise Lex trisaccharide antigen [1][2][3][4][5][6]. With this in mind, we focus our research on the discovery of analogues of dimLex that can be used as safe vaccine candidates. Ideally, these analogues should display the internal epitopes that are recognized by anti-dimLex SH2-like antibodies
The use of glycoinformatics in glycochemistry
Beilstein J. Org. Chem. 2012, 8, 915–929, doi:10.3762/bjoc.8.104
- , classifications, and information regarding related diseases. GlycoEpitopeDB provides information on antibodies that recognize specific carbohydrate epitopes and glycoproteins or glycolipids that are known to carry the epitopes. A frequently used technique to study the epitopes, to which a GBP binds, are glycan
Synthetic glycopeptides and glycoproteins with applications in biological research
Beilstein J. Org. Chem. 2012, 8, 804–818, doi:10.3762/bjoc.8.90
- applications, in which glycopeptides or glycoproteins serve as tools for biological studies, are reviewed. The importance of specific antibodies directed to the glycan part, as well as the peptide backbone has been realized during the development of synthetic glycopeptide-based anti-tumor vaccines. The fine
- a number of cases [28][29][34]. Furthermore, several antibodies induced by the vaccines showed specific recognition of tumor cells. The MUC1 tandem repeat glycopeptides were synthesized on solid-phase, according to the Fmoc strategy, by using Fmoc protected amino acids and Fmoc glycosyl amino acid
- T-antigen, or a difluoro-T-antigen on different positions in the tandem repeat (6–10), showed that high antibody titers were induced in almost all of the immunized mice. Evaluation of the generated antibodies provided evidence that specific immune responses were elicited towards the MUC1 antigens
An easily accessible sulfated saccharide mimetic inhibits in vitro human tumor cell adhesion and angiogenesis of vascular endothelial cells
Beilstein J. Org. Chem. 2012, 8, 787–803, doi:10.3762/bjoc.8.89
- oligosaccharides interacting with the respective binding partners on neighboring cells. In this respect our results are reminiscent of a previous study in which we described the inhibition of endothelial networking by monoclonal antibodies against the histo blood group oligosaccarides Lewisy and H and further by
Triterpenoid saponins from the roots of Acanthophyllum gypsophiloides Regel
Beilstein J. Org. Chem. 2012, 8, 763–775, doi:10.3762/bjoc.8.87
- bark, or without an adjuvant, and the specific anti-3’SL IgM and IgG responses were evaluated. For saponins 1 and 2, a significant specific response was observed in comparison with the control vaccine formulation with antigen alone (Table 6). High serum titers of IgM and IgG antibodies were registered
- in the vaccination with compound 1 as adjuvant, though the IgG level did not achieve the level measured in the experiment with saponin from Quillaja bark. Titers of those antibodies in the experiment with saponin 2 were rather low. We can conclude, that in combination with 3’SL-KLH, antigen compound
Chemo-enzymatic modification of poly-N-acetyllactosamine (LacNAc) oligomers and N,N-diacetyllactosamine (LacDiNAc) based on galactose oxidase treatment
Beilstein J. Org. Chem. 2012, 8, 712–725, doi:10.3762/bjoc.8.80
- summary, these novel neo-glycoconjugates are interesting tools for extensive binding studies of a variety of glycan binding proteins (lectins, antibodies) and for possible therapeutic applications. Conclusion Novel poly-LacNAc derivatives have been produced on a micro-gram scale, which can be used for
Convergent synthesis of the tetrasaccharide repeating unit of the O-antigen of Shigella boydii type 9
Beilstein J. Org. Chem. 2011, 7, 1182–1188, doi:10.3762/bjoc.7.137
- therapeutics than the earlier used anti-shigellosis agents [9][10]. Because of the high antigenic nature of the O-antigens, antibodies against the O-specific polysaccharide of a particular Shigella strain have the potential to control Shigella infections [11][12][13][14]. A number of reports have been cited
Catalysis: transition-state molecular recognition?
Beilstein J. Org. Chem. 2010, 6, 1026–1034, doi:10.3762/bjoc.6.117
- objectives, such as the design of TS analogues as potential drugs, or the design of synthetic catalysts (including catalytic antibodies), require prior knowledge of the TS structure to be mimicked. Examples, both old and new, of computational modelling studies are discussed, which illustrate this fundamental
- decrease in the energy of activation” [4]. A corollary to this insight was provided by W. P. (Bill) Jencks, who noted that a catalyst might be synthesised by raising an antibody to a hapten resembling the TS of the reaction to be catalysed: “the combining sites of such antibodies should be complementary to
- expected to compete successfully with the substrate in combining with the enzyme, which in this respect would be similar in behaviour to antibodies; but an enzyme complementary to a strained substrate molecule would attract more strongly to itself a molecule resembling the strained substrate molecule than
Synthesis of 6-PEtN-α-D-GalpNAc-(1–>6)-β-D-Galp-(1–>4)-β-D-GlcpNAc-(1–>3)-β-D-Galp-(1–>4)-β-D-Glcp, a Haemophilus influenzae lipopolysacharide structure, and biotin and protein conjugates thereof
Beilstein J. Org. Chem. 2010, 6, 704–708, doi:10.3762/bjoc.6.80
- , i.e. the bacteria express common human carbohydrate structures on their surface that the host recognises as self-structures and do not produce antibodies against. Construction of a glycoconjugate vaccine against NTHi is thus quite complex. Carbohydrate structures that are both exposed on the surface
- examined. Compound 23 was also biotinylated for use in ELISA-screening of antibodies raised against native LPS. Reaction with the commercial NHS-activated ester of biotin followed by TFA-treatment to remove the Boc-group afforded derivative 25. The H. influenzae outer core target structure. i. BH3, Bu2BOTf
RAFT polymers for protein recognition
Beilstein J. Org. Chem. 2010, 6, No. 66, doi:10.3762/bjoc.6.66
- where antibodies are generated in response to minute amounts of foreign antigens. A continual challenge in nanoscale chemistry is to mimic the biological molecular recognition functions by synthetic chemistry with the aim of producing systems of lower complexity. When successful, this will enable the
An expedient synthesis of 5-n-alkylresorcinols and novel 5-n-alkylresorcinol haptens
Beilstein J. Org. Chem. 2009, 5, No. 22, doi:10.3762/bjoc.5.22
- describes the synthesis of two 1-phenylalkenes in 20–30% yield using benzaldehyde and a CH2Cl2/H2O solvent [31]. We report here a fast and efficient synthesis of the long chain 5-n-alkylresorcinols 1 and the new potential hapten derivatives of 5-n-alkylresorcinols 2, ready for the development of antibodies
Synthesis of imidazol- 1-yl-acetic acid hydrochloride: A key intermediate for zoledronic acid
Beilstein J. Org. Chem. 2008, 4, No. 42, doi:10.3762/bjoc.4.42
- . Zoledronic acid is also used along with the cancer chemotherapy to treat bone damage caused by multiple myeloma (a type of cancer of plasma cells that are part of the immune system cells in bone marrow and produce antibodies) or by cancer that began in another part of the body but has spread to the bones
Colchitaxel, a coupled compound made from microtubule inhibitors colchicine and paclitaxel
Beilstein J. Org. Chem. 2006, 2, No. 13, doi:10.1186/1860-5397-2-13
- Laboratories (San Francisco, CA), was diluted 1:100. As secondary antibodies, FITC-conjugated (U. S. Biochemical Corp., Cleveland, OH) or Alexa 488-conjugated goat anti-mouse immunoglobulin G (Molecular Probes, Eugene, OR) were used as described previously [17]. Wide-field fluorescence images were recorded on
Other Beilstein-Institut Open Science Activities
